NOVEL ERA

Abstract: The invention provides era polypeptides and DNA (RNA) encoding era polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing era polypeptides to screen for antibacterial compounds.

Description: NOVEL era FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and pol peptides. and their production and uses, as well as their vanants. agonists and antagonists, and their uses In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the GTP -binding protein family, hereinafter referred to as "era" BACKGROUND OF THE INVENTION The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including for example otitis media conjunctivitis, pneumonia bactererraa. meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid Since its isolation more than 100 years ago, Streptococcus pneumomae has been one of the more intensively studied microbes For example, much of our early understanding that DNA is. in fact, the genetic matenal was predicated on the work of Gπffith and of Avery, Macleod and McCarty using this microbe Despite the vast amount of research w th Streptococcus pneumomae, many questions concerning the virulence of this microbe remain It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics The frequency of Streptococcus pneumomae infections has πsen dramatically in the past 20 years This has been attnbuted to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune s stems It is no longer uncommon to isolate Streptococcus pneumomae strains which are resistant to some or all of the standard antibiotics This has created a demand for both new anti-microbial agents and diagnostic tests for this organism Proteins essential for growth of bactenal make excellent candidates for anti-infectr e agents GTPases play important physiological roles in both prokar otic and eukaryotic cells Regulatory GTPases consist of GTP-binding domains conserved through evolution (H R Bourne, et al Nature 349 117-127 (1991)) Biological activity is controlled by conformational changes which occur when a bound GTP molecule is bound or released by hydrolysis to GDP In additon to the conserved GTP-binding domains, bactenal GTPases share other conserved protein domains (K Zuber. et al . Gene 189 31-34 (1997) Era is a GTP-binding protein essential for growth in Escherichia coli (N Gollop & P E March J Bacteπol 173 2265-2270 (1991), H E Takiff, et al J Bactenol 171 2581-90 (1989)). and other Gram-negative bactena A homolog in S mutans. spg. is important for adaptation to environmental stresses (Y Ya ashita et al J Bactenol 175 6220- 6228) Mutations in era proteins cause a loss of cell viability or a decreased abilty to respond to stresses that occur when a pathogen invades a host Inhibitors of era GTPases would interfere with lntracellular signalling necessary for normal growth as ell as adaptation to environmental changes such as that which occurs when a pathogen invades a host and would therefore be lethal or inhibitory to the bactenum and thereby have utility in anti-bactenal therapy Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dy sfunction and disease There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases The polypeptides of the invention have amino acid sequence homology to a known era protein (Swiss-Prot Accession Number P37214, GenBank Accession Number L03428) SUMMARY OF THE INVENTION It is an object of the invention to provide polypeptides that have been identified as novel era polypeptides by homology between the ammo acid sequence set out m Table 1 [SEQ ID NO 2] and a known amino acid sequence or sequences of other proteins such as era protein It is a further object of the invention to provide polynucleotides that encode era polypeptides, particularly polynucleotides that encode the polypeptide herein designated era In a particularly preferred embodiment of the invention, the polynucleotide compnses a region encoding era polypeptides compnsmg the sequence set out in Table 1 [SEQ ID NO 1] which includes a full length gene, or a vanant thereof In another particularly preferred embodiment of the mvention, there is a novel era protein from Streptococcus pneumomae compnsmg the ammo acid sequence of Table 1 [SEQ ID NO 2]. or a vanant thereof In accordance with another aspect of the invention, there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Streptococcus pneumomae 0100993 strain contained in the deposited strain As a further aspect of the invention, there are provided isolated nucleic acid molecules encoding era, particularly Streptococcus pneumomae era. including mRNAs, cDNAs. genomic DNAs Further embodiments of the invention include biologically, diagnostically prophylactically, clinically or therapeuϋcally useful vanants thereof, and compositions compnsmg the same In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, m particular genetic immunization Among the particularly preferred embodiments of the invention are naturally occurring allehc vanants of era and polypeptides encoded thereby As another aspect of the invention, there are provided novel polypeptides of Streptococcus pneumomae referred to herein as era as well as biologically, diagnostically, prophylactically. clinically or therapeutically useful vanants thereof, and compositions compnsmg the same Among the particularly preferred embodiments of the invention are vanants of era polypeptide encoded by naturally occurring alleles of the era gene In a preferred embodiment of the invention, there are provided methods for producing the aforementioned era polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides. useful as antibacterial agents, including, for example, antibodies In accordance with certain preferred embodiments of the mvention, there are provided products, compositions and methods for assessmg era expression, treatmg disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic vanation, and administering a era polypeptide or polynucleotide to an organism to raise an lmmunological response against a bactena, especially a Streptococcus pneumomae bactena In accordance with certain preferred embodiments of this and other aspects of the mvention. there are provided polynucleotides that hybndize to era polynucleotide sequences, particularly under stringent conditions In certain preferred embodiments of the mvention, there are provided antibodies against era polypeptides In other embodiments of the mvention, there are provided methods for identifying compounds which bmd to or otherwise interact w th and inhibit or activate an activity of a polypeptide or polynucleotide of the mvention compnsmg contacting a polypeptide or polynucleotide of the mvention with a compound to be screened under conditions to permit bmdmg to or other mteraction between the compound and the polypeptide or polynucleotide to assess the bmdmg to or other mteraction with the compound, such bmdmg or mteraction bemg associated with a second component capable of providing a detectable signal m response to the bmdmg or mteraction of the polypeptide or polynucleotide with the compound, and determining whether the compound binds to or otherwise interacts w th and activates or inhibits an activity of the polypeptide or polynucleotide by detectmg the presence or absence of a signal generated from the bmdmg or mteraction of the compound with the polypeptide or polynucleotide In accordance with yet another aspect of the mvention, there are provided era agonists and antagonists, preferably bactenostatic or bactenocidal agonists and antagonists In a further aspect of the mvention. there are provided compositions compnsmg a era polynucleotide or a era polypeptide for administration to a cell or to a multicellular organism Vanous changes and modifications within the spint and scope of the disclosed w ll become readily apparent to those skilled m the art from reading the following descnptions and from reading the other parts of the present disclosure GLOSSARY The following definitions are provided to facilitate understanding of certain terms used frequently herem "Host cell" is a cell which has been transformed or transfected. or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity." as known m the art. is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match betw een stnngs of such sequences "Identity" and "similanty" can be readily calculated by known methods, mcludmg but not limited to those descnbed m (Computational Molecular Biology. Lesk. A M . ed . Oxford University Press, New York. 1988, Bwcomputing Informatics and Genome Projects. Smith. D W , ed , Academic Press, New York, 1993, Computer Analysis of Sequence Data. Part I, Gnffin, A M , and Gnffin. H G . eds . Humana Press. New Jersey. 1994. Sequence Analysis in Molecular Biology, von Hemje, G , Academic Press, 1987. and Sequence Analysis Primer, Gnbskov, M and Devereux. J , eds , M Stockton Press. New York, 1991. and Canllo. H , and Lipman. D , SIAM J Applied Math , 48 1073 (1988) Preferred methods to determine identity are designed to give the largest match between the sequences tested Methods to determine identity and similanty are codified in publicly available computer programs Prefeπed computer program methods to determine identity and similanty between two sequences include, but are not limited to. the GCG program package (Devereux. J et al , Nucleic Acids Research 12(1) 387 (1984)). BLASTP, BLASTN, and FASTA (Atschul. S F et al . J Molec Biol 215 403-410 (1990) The BLAST X program is publiclv available from NCBI and other sources (BLAST Manual Altschul, S . et al . NCBI NLM NIH Bethesda. MD 20894, Altschul. S . et al , J Mol Biol 215 403-410 (1990) As an illustration, by a polynucleotide having a nucleotide sequence having at least for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1 In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides m the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either ldually among nucleotides in the reference sequence or in one or more contiguous groups withm the reference sequence Analogously . by a polypeptide havmg an ammo acid sequence having at least, for example. 95% identity to a reference amino acid sequence of SEQ ID NO 2 is intended that the ammo acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five ammo acid alterations per each 100 ammo acids of the reference ammo acid of SEQ ID NO 2 In other words, to obtam a polypeptide having an ammo acid sequence at least 95% identical to a reference ammo acid sequence, up to 5% of the ammo acid residues m the reference sequence may be deleted or substituted with another ammo acid, or a number of amino acids up to 5% of the total ammo acid residues in the reference sequence may be inserted mto the reference sequence These alterations of the reference sequence may occur at the ammo or carboxy terminal positions of the reference ammo acid sequence or anywhere between those terminal positions, mterspersed either individually among residues m the reference sequence or in one or more contiguous groups within the reference sequence "Isolated" means altered "by the hand of man" from its natural state, l e , if it occurs m nature, it has been changed or removed from its oπginal environment or both For example, a polynucleotide or a polypeptide naturally present m a living organism is not "isolated. " ' but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is "isolated", as the term is employed herem "Polynucleotιde(s)" generally refers to any polynbonucleotide or polydeoxnbonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA "Polynucleotιde(s)" include, without limitation, smgle- and double-stranded DNA. DNA that is a mixture of smgle- and double- stranded regions or smgle-. double- and tnple-stranded regions, smgle- and double-stranded RNA. and RNA that is mixture of smgle- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of smgle- and double-stranded regions In addition, "polynucleotide" as used herein refers to tnple-stranded regions compnsmg RNA or DNA or both RNA and DNA The strands m such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically invoh e only a region of some of the molecules One of the molecules of a tiiple-hehcal region often is an o gonucleotide As used herem, the term "polynucleotide(s)" also includes DNAs or RNAs as descnbed above that contain one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotιde(s)" as that term is mtended herem Moreover. DNAs or RNAs compnsmg unusual bases, such as mosme. or modified bases, such as tntylated bases, to name ust two examples, are polynucleotides as the term is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill m the art The term "polynucleotide(s)" as it is employed herem embraces such chemically, enzymatically or metabolically modified forms of polynucleotides. as well as the chemical forms of DNA and RNA charactenstic of viruses and cells, including, for example, simple and complex cells "Polynucleotιde(s)" also embraces short polynucleotides often refened to as olιgonucleotide(s) "Polypeptide(s)" refers to any peptide or protem compnsmg two or more ammo acids jomed to each other by peptide bonds or modified peptide bonds "Polypeptιde(s)" refers to both short chains, commonly refened to as peptides. ohgopeptides and ohgomers and to longer chains generally referred to as proteins Polypeptides may contain ammo acids other than the 20 gene encoded ammo acids "Polypeptιde(s)" mclude those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as m a voluminous research literature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present m the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contain many types of modifications Modifications can occur anywhere in a polypeptide. including the peptide backbone, the ammo acid side-chains, and the ammo or carboxyl termini Modifications mclude. for example, acetylation, acylation. ADP-nbosylation. amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide denvatrve. covalent attachment of a lipid or hpid denvative. covalent attachment of phosphotidy linositol. cross-linking. cyclization, disulfide bond formation, demethylation. formation of covalent cross-links, formation of cysteine. formation of pyroglutamate. formylation. gamma-carboxylation. gKcosylation. GPI anchor formation, hydroxylation. lodination, methylation. myπstoylation. oxidation, proteolytic processmg. phosphorylation, prenylation. racemization. glycosylation. lipid attachment, sulfation. gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation. selenov lation. sulfation. transfer-RNA mediated addition of ammo acids to proteins, such as arginvlation. and ubiquitination See, for instance. PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES 2nd Ed . T E Creighton, W H Freeman and Company. New York (1993) and Wold. F . Posttranslational Protem Modifications Perspectives and Prospects, pgs 1-12 m POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS. B C Johnson. Ed . Academic Press. New York (1983), Seifter et al .Meth Enzvmol 182 626-646 (1990) and Rattan et al , Protein Synthesis Posttranslational Modifications and Aging. Ann Y Acad Sci 663 48- 62 (1992) Polypeptides may be branched or cyclic, w th or without branching Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well ' Nanant(s) " ' as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retams essential properties A typical vanant of a polynucleotide differs m nucleotide sequence from another, reference polynucleotide Changes in the nucleotide sequence of the vanant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below A typical vanant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference polypeptide and the vanant are closely similar overall and. in many regions, identical A vanant and reference polypeptide may differ m amino acid sequence by one or more substitutions, additions, deletions m any combmation A substituted or inserted amino acid residue may or may not be one encoded by the genetic code A vanant of a polynucleotide or polypeptide may be a naturally occurnng such as an allehc vanant, or it may be a vanant that is not known to occur naturally Non- naturally occurnng vanants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans DESCRIPTION OF THE INVENTION The mvention relates to novel era polypeptides and polynucleotides as descnbed m greater detail below In particular, the mvention relates to polypeptides and polynucleotides of a no \ el era of Streptococcus pneumomae. which is related b\ ammo acid sequence homology to known era polypeptide (Swiss-Prot Accession Number P37214 GenBank Accession Number L03428) The mvention relates especially to era havmg the nucleotide and ammo acid sequences set out in Table 1 [SEQ ID NO IJ and Table 1 [SEQ ID NO 2J respectively, and to the era nucleotide sequences of the DNA m the deposited strain and ammo acid sequences encoded therebv TABLE 1 era Polynucleotide and Polypeptide Sequences (A) Sequences from Streptococcus pneumomae era polynucleotide sequence [SEQ ID NO 1] 5 ' - ATGACTTTTAAATCAGGCTTTGTAGCCATTTTAGGACGTCCCAATGTTGGGAAGTCAACC TTTTTAAATCACGTTATGGGGCAAAAGATTGCCATCATGAGTGACAAGGCGCAGACAACG CGCAATAAAATCAT GGGAATTTACACGACT GA AAGGAGCAAATT GT CTTTAT CGACACA CCAGGGATTCACAAACCTAAAACAGCTCTCGGAGATTTCATGGTTGAGTCTGCCTACAGT ACCCTTCGCGAAGTGGACACTGTTCTTTTCATGGTGCCTGCTGATGAAGCGCGTGGTAAG GGGGACGATATGATTATCGAGCGTCTCAAGGCTGCCAAGGTTCCTGTGATTTTGGTGGTG AATAAAATCGATAAGGTCCATCCAGACCAGCTCTTGTCTCAGATTGATGACTTCCGTAAT CAAATGGACTTTAAGGAAATTGTTCCAATCTCAGCCCTTCAGGGAAATAACGTGTCTCGT CTAGTGGATATTTTGAGTGAAAATCTGGATGAAGGTTTCCAATATTTCCCGTCTGATCAA ATCACAGACCATCCAGAACGTTTCTTAGTTTCAGAAATGGTTCGCGAGAAAGTCTTGCAC CTAACTCGTGAAGAGATTCCGCATTCTGTAGCAGTAGTTGTTGACTCTATGAAACGAGAC GAAGAGACAGACAAGGTTCACATCCGTGCAACCATCATGGTCGAGCGCGATAGCCAAAAA GGGATTATCATCGGTAAAGGTGGCGCTATGCTTAAGAAAATCGGTAGCATGGCCCGTCGT GATATCGAACTCATGCTAGGAGACAAGGTCTTCCTAGAAACCTGGGTCAAGGTCAAGAAA AACTGGCGCGATAAAAAGCTAGATTTGGCTGACTTGGGCTATAATGAAAGAGAATACTAA- 3 ' (B) era polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO 2] NH C -MTFKSGFVAILGRPNVGKSTFLNHVMGQKIAIMSDKAQTTRNKIMGIYTTDKEQIVFIDT PGIHKPKTALGDrTMVESAYSTLREVDTλ LFMVPADEARGKGDDMI IERLKAAKVPVI LVV NKIDK /HPDQLLSQIDDFRNQMDFKEIVPI SALQGNNVSRLVDI LSENLDEGFQYFPSDQ ITDHPERFLVSE^ VREKVLHLTREEI PHSVAλΛA DSMKRDEETDKVHI RATI 4 ERDSQK GI I IGKGGAMLKKIGSMARRDI ELMLGDKVFLETWVKVKKNWRDKKLDLADLGYNEREY -COOH (C) Polynucleotide sequence embodiments [SEQ ID NO 1] X- (R ] _ ) n -ATGACTTTTAAATCAGGCTTTGTAGCCATTTTAGGACGTCCCAATGTTGGGAAGTCAACC TTTTTAAATCACGTTATGGGGCAAAAGATTGCCATCATGAGTGACAAGGCGCAGACAACG CGCAATAAAATCATGGGAATTTACACGACTGATAAGGAGCAAATTGTCTTTATCGACACA CCAGGGATTCACAAACCTAAAACAGCTCTCGGAGATTTCATGGTTGAGTCTGCCTACAGT ACCCTTCGCGAAGTGGACACTGTTCTTTTCATGGTGCCTGCTGATGAAGCGCGTGGTAAG GGGGACGATATGATTATCGAGCGTCTCAAGGCTGCCAAGGTTCCTGTGATTTTGGTGGTG AATAAAATCGATAAGGTCCATCCAGACCAGCTCTTGTCTCAGATTGATGACTTCCGTAAT CAAATGGACTTTAAGGAAATTGTTCCAATCTCAGCCCTTCAGGGAAATAACGTGTCTCGT CTAGTGGATATTTTGAGTGAAAATCTGGATGAAGGTTTCCAATATTTCCCGTCTGATCAA ATCACAGACCATCCAGAACGTTTCTTAGTTTCAGAAATGGTTCGCGAGAAAGTCTTGCAC CTAACTCGTGAAGAGATTCCGCATTCTGTAGCAGTAGTTGTTGACTCTATGAAACGAGAC GAAGAGACAGACAAGGTTCACATCCGTGCAACCATCATGGTCGAGCGCGATAGCCAAAAA GGGATTATCATCGGTAAAGGTGGCGCTATGCTTAAGAAAATCGGTAGCATGGCCCGTCGT GATATCGAACTCATGCTAGGAGACAAGGTCTTCCTAGAAACCTGGGTCAAGGTCAAGAAA AACTGGCGCGATAAAAAGCTAGATTTGGCTGACTTGGGCTATAATGAAAGAGAATACTAA- ( R 2 ) n -Y (D) Polypeptide sequence embodiments [SEQ ID NO:2]. X- (R 1 ) n -MTFKSGFVAILGRPNVGKSTFLNHλ GQKIAIMSDKAQTTRNKIMGIYTTDKEQIVFIDT PGIHKPKTALGDFMVESAYSTLREVDTVLFMVPADEARGKGDDMIIERLKAAfVPVILVV' NKIDKVHPDQLLSQIDDFRNQMDFKEIVPISALQGNNVSRLVDILSENLDEGFQYFPSDQ I DHPERFLVSEMVREKVLHL REEIPHSVAλWDSMKRDEETDKVHIR TI4VERDSQK GUIGKGGAMLKKIGSMARRDIELMLGDKVFLET VKVKKNWRDKK DLADLGYNEREY - ( R 2 > n - γ (E) Sequences from Streptococcus pneumoniae era polynucleotide ORF sequence [SEQ ID NO:3]. 5 ' -ATGACTTTTAAATCAGGCTTTGTAGCCATTTTAGGACGTCCCAATGTTGGGAAGTCAACC TTTTTAAATCACGTTATGGGGCAAAAGATTGCCATCATGAGTGACAAGGCGCAGACAACG CGCAATAAAATCATGGGAATTTACACGACTGATAAGGAGCAAATTGTCTTTATCGACACA CCAGGGATTCACAAACCTAAAACAGCTCTCGGAGATTTCATGGTTGAGTCTGCCTACAGT ACCCTTCGCGAAGTGGACACTGTTCTTTTCATGGTGCCTGCTGATGAAGCGCGTGGTAAG GGGGACGATATGATTATCGAGCGTCTCAAGGCTGCCAAGGTTCCTGTGATTTTGGTGGTG AATAAAATCGATAAGGTCCATCCAGACCAGCTCTTGTCTCAGATTGATGACTTCCGTAAT CAAATGGACTTTAA-3 ' (F) era polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO:4], NH 2 -MTFKΞGFVAI LGRPNVGKSTFLNHVMGQKIAIMSDKAQTTRNKIMGIYTTDKEQIVFI DT PGIHKPKTALGDFMVESAYSTLREVDTVLFMVPADEARGKGDDMI I ERLKAAKVPVILW NKIDKVHPDQLLSQI DDFRNQMDF -COOH Deposited materials A deposit containing a Streptococcus pneumomae 0100993 stram has been deposited with the National Collections of Industnal and Marine Bactena Ltd (herem "NCIMB " ). 23 St Machar Dnve. Aberdeen AB2 1RY. Scotland on 11 Apnl 1996 and assigned deposit number 40794 The deposit was descnbed as Streptococcus pneumomae 0100993 on deposit On 17 Apnl 1996 a Streptococcus pneumomae 0100993 DNA library in E coli was similarly deposited with the NCIMB and assigned deposit number 40800 The Streptococcus pneumomae stram deposit is refened to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited stram contains the fiill length era gene The sequence of the polynucleotides contamed in the deposited stram. as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any descnption of sequences herem The deposit of the deposited stram has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The stram will be urevocably and without restnction or condition released to the public upon the issuance of a patent The deposited stram is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited stram. and compounds denved therefrom, and no such license is hereby granted Polypeptides The polypeptides of the mvention mclude the polypeptide of Table 1 [SEQ ID NO 2] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of era, and also those which have at least 92% identity to a polypeptide of Table 1 [SEQ ID NOS 2 and 4] or the relevant portion, preferably at least 93% identity, more preferably at least 95% identity to a polypeptide of Table 1 [SEQ ID NOS 2 and 4]. and more preferably at least 97% similanty (more preferably at least 97% identity) to a polypeptide of Table 1 [SEQ ID NOS 2 and 4] and still more preferably at least 98% similanty (still more preferably at least 98% identity) to a polypeptide of Table 1 [SEQ ID NOS 2 and 4] and also mclude portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula set forth m Table 1 (D) [SEQ ID NO 2] vvherem, at the ammo terminus. X is hydrogen, and at the carboxyl terminus. Y is hydrogen or a metal. Ri and R2 is any ammo acid residue, and n is an mteger between 1 and 1000 Any stretch of ammo acid residues denoted by either R group where R is greater than 1. may be either a heteropolymer or a homopolymer, preferably a heteropolymer A fragment is a vanant polypeptide havmg an ammo acid sequence that entirely is the same as part but not all of the am o acid sequence of the aforementioned polypeptides As with era polypeptides fragments may be "free-standing." or compnsed within a larger polypeptide of which they form a part or region, most preferably as a smgle cont uous region, a smgle larger polypeptide Prefened fragments mclude. for example, truncation polypeptides havmg a portion of an ammo acid sequence of Table 1 [SEQ ID NOS 2 and 4], or of vanants thereof, such as a contmuous senes of residues that mcludes the ammo termmus. or a contmuous senes of residues that includes the carboxyl termmus Degradation forms of the polypeptides of the mvention m a host cell, particularly a Streptococcus pneumomae. are also prefened Further prefened are fragments characterized by structural or functional attnbutes such as fragments that compπse alpha-helrx and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-formmg regions, substrate bmdmg region, and high antigenic mdex regions Also prefened are biologically active fragments which are those fragments that mediate activities of era, including those with a similar activity or an improved activity, or with a decreased undesirable activity Also mcluded are those fragments that are antigenic or immunogemc m an ammal. especially m a human Particularly prefened are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Streptococcus pneumomae or the ability to initiate, or maintain cause disease m an individual, particularly a human Vanants that are fragments of the polypeptides of the mvention may be employed for producmg the conespondrng full-lengtb. polypeptide by peptide synthesis, therefore, these vanants may be employed as intermediates for producmg the full-length polypeptides of the mvention Polynucleotides Another aspect of the mvention relates to isolated polynucleotides, including the full length gene, that encode the era polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ID NOS 2 and 4] and polynucleotides closely related thereto and vanants thereof Usmg the information provided herem. such as a polynucleotide sequence set out m Table 1 [SEQ ID NOS 1 and 3]. a polynucleotide of the mvention encoding era polypeptide may be obtained usmg standard cloning and screening methods, such as those for cloning and sequencmg chromosomal DNA fragments from bactena usmg Streptococcus pneumomae 0100993 cells as starting mateπal. followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the invention, such as a sequence given Table 1 [SEQ ID NOS 1 and 3] typically a library of clones of chromosomal DNA of Streptococcus pneumomae 0100993 in E coli or some other suitable host is probed with a radiolabeled ohgonucleotide. preferably a 17-mer or longer, denved from a partial sequence Clones carrving DNA identical to that of the probe can then be distinguished using stringent conditions By sequencmg the individual clones thus identified with sequencmg pπmers designed from the onginal sequence it is then possible to extend the sequence in both directions to determine the full gene sequence Conveniently, such sequencing is performed usmg denatured double stranded DNA prepared from a plasmid clone Suitable techniques are descnbed by Mamatis. T , Fntsch. E F and Sambrook et al . MOLECULAR CLONING A LABORATORY MANUAL 2nd Ed . Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989) (see m particular Screening By Hybridization 1 90 and Sequencmg Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention, the polynucleotide set out m Table 1 [SEQ ID NO 1] was discovered in a DNA library denved from Streptococcus pneumomae 0100993 The DNA sequence set out in Table 1 [SEQ ID NOS 1] contains an open reading frame encodmg a protem havmg about the number of ammo acid residues set forth m Table 1 [SEQ ID NO 2] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known m the art The polynucleotide of SEQ ID NO 1. between nucleotide number 1 through number 897 encodes the polypeptide of SEQ ID NO 2 The stop codon begins at nucleotide number 898 of SEQ ID NO 1 The era polypeptode of the mvention is structurally related to other protems of the GTP- binding protem family, as shown by the results of sequencmg the DNA encodmg era of the deposited stram The protem exhibits greatest homology to era protem among known proteins The era polypeptide of Table 1 [SEQ ID NO 2] has about 91 6% identity over its entire length and about 96 0% similanty over its entire length with the ammo acid sequence of a known era polypeptide The mvention provides a polynucleotide sequence identical over its entire length to the coding sequence m Table 1 [SEQ ID NO 1] Also provided by the mvention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment m reading frame with other coding sequence, such as those encodmg a leader or secretory sequence, a pre-, or pro- or prepro- protem sequence The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5 " and 3' sequences, such as the transcnbed. non-translated sequences, termination signals, πbosome bmdmg sites, sequences that stabilize mRNA. mtrons. polyadenylation signals, and additional coding sequence which encode additional ammo acids For example, a marker sequence that facilitates punfication of the fused polypeptide can be encoded In certain embodiments of the mvention, the marker sequence is a hexa-histidine peptide. as provided m the pQE vector (Qiagen. Ine ) and descnbed in Gentz et al . Proc Natl Acad Sci USA 86 821-824 (1989). or an HA tag (Wilson et al . Cell 37 IGl (1984) Polynucleotides of the mvention also mclude. but are not limited to. polynucleotides compnsmg a structural gene and its naturally associated sequences that control gene expression A prefened embodiment of die mvention is a polynucleotide of compnsmg nucleotide 1 to 898 or 900 set forth m SEQ ID NO 1 of Table 1 which encode the era polypeptide The mvention also mcludes polynucleotides of the formula set forth m Table 1 (C)[SEQ ID NO 1] wherem. at the 5' end of the molecule. X is hydrogen, and at the 3' end of the molecule. Y is hydrogen or a metal. Rj and R2 is any nucleic acid residue, and n is an mteger between 1 and 1000 Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1 may be either a heteropolymer or a homopolymer. preferably a heteropolymer The term "polynucleotide encodmg a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encodmg a polypeptide of the mvention. particularly a bactenal polypeptide and more particularly a polypeptide of the Streptococcus pneumomae era havmg the ammo acid sequence set out in Table 1 [SEQ ID NO 2] The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encodmg the polypeptide (for example, interrupted by mtegrated phage or an insertion sequence or editing) together w th additional regions, that also may contain coding and/or non-coding sequences The mvention further relates to vanants of the polynucleotides descnbed herem that encode for vanants of the polypeptide havmg the deduced ammo acid sequence of Table 1 [SEQ ED NO 2] Vanants that are fragments of the polynucleotides of the mvention may be used to synthesize fiill- length polynucleotides of the mvention Further particularly prefened embodiments are polynucleotides encodmg era vanants. that have the ammo acid sequence of era polypeptide of Table 1 [SEQ ID NO 2] m which several, a few. 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, m any combination Especially prefened among these are silent substitutions, additions and deletions, that do not alter the properties and activities of era Further prefened embodiments of the mvention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encodmg era polypeptide havmg an ammo acid sequence set out m Table 1 [SEQ ID NOS 2 and 4]. and polynucleotides that are complementary to such polynucleotides Alternatively, more prefened are polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encodmg era polypeptide of the deposited stram and polynucleotides complementary thereto In this regard, polvnucleotides at least 90% identical over their entire length to the same are prefened. those with at least 92% identity are more prefened. and among these particularly prefened polynucleotides. those with at least 95% are especially prefened Furthermore, those with at least 97% are highly prefened among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly prefened. with at least 99% bemg the more prefened Prefened embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO 1] The mvention further relates to polynucleotides that hybndize to the herem above-descnbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stringent conditions to the herem above-descnbed polynucleotides As herem used, the terms "stringent conditions" and "stringent hybndization conditions" mean hybndization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of stnngent hybndization conditions is overnight incubation at 42°C m a solution compnsmg 50% formamide, 5x SSC (150mM NaCl. 15mM tnsodium citrate). 50 mM sodium phosphate (pH7 6). 5x Denhardt's solution, 10% dextran sulfate. and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybndization support in 0 lx SSC at about 65°C Hybndization and wash conditions are well known and exemplified m Sambrook. et al . Molecular Clonmg A Laboratory Manual. Second Edition. Cold Spπng Harbor. N Y . (1989). particularly Chapter 11 therein The mvention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtamable by screenmg an appropnate library containing the complete gene for a polynucleotide sequence set forth m SEQ ID NO 1 or SEQ ID NO 3 under stnngent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth m SEQ ID NO 1 or a fragment thereof, and isolating said DNA sequence Fragments useful for obtaining such a polynucleotide include, for example, probes and pnmers descnbed elsewhere herein As discussed additionally herem regarding polynucleotide assa s of the mvention. for instance, polynucleotides of the mvention as discussed above, may be used as a hybndization probe for RNA. cDNA and genomic DNA to isolate full-length cDNAs and geno ic clones encodmg era and to isolate cDNA and genomic clones of other genes that have a high sequence similanty to the era gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefened probes will have at least 30 bases and will have 50 bases or less For example, the coding region of the era gene mav be isolated bv screening usmg the DNA sequence provided in SEQ ID NO 1 to synthesize an ohgonucleotide probe A labeled ohgonucleotide having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and matenals for discoverv of treatments of and diagnostics for disease particularly human disease, as further discussed herem relating to polynucleotide assay s Polynucleotides of the invention that are oligonucleotides den ed from the sequences of SEQ ID NOS 1 and/or 2 may be used in the processes herein as descnbed. but preferably for PCR to determine whether or not the polynucleotides identified herem m whole or in part are transcnbed in bactena in infected tissue It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained The mvention also provides polynucleotides that may encode a polypeptide that is the mature protem plus additional ammo or carboxvl-terminal ammo acids, or ammo acids mteπor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance) Such sequences may play a role m processing of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facilitate manipulation of a protem for assay or production, among other things As generally is the case in vivo, the additional ammo acids may be processed away from the mature protem by cellular enzymes A precursor protein, havmg the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be remov ed before activation Generall , such precursors are called proproteins In sum, a polynucleotide of the mvention may encode a mature protein, a mature protem plus a leader sequence (which may be refened to as a preprotem). a precursor of a mature protem havmg one or more prosequences that are not the leader sequences of a preprotem. or a preproprotem. which is a precursor to a proprotem. havmg a leader sequence and one or more prosequences. which generally are removed during processing steps that produce active and mature forms of the polypeptide Vectors, host cells, expression The mvention also relates to vectors that compnse a polvnucleotide or polynucleotides of the mvention, host cells that are genetically engmeered with vectors of the mvention and the production of polypeptides of the mvention by recombinant techniques Cell-free translation systems can also be employed to produce such proteins usmg RNAs denved from the DNA constructs of the mvention For recombinant production, host cells can be genetically engmeered to incorporate expression systems or portions thereof or polynucleotides of die mvention Introduction of a polynucleotide mto the host cell can be effected by methods descnbed m many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY. (1986) and Sambrook et al . MOLECULAR CLONING A LABORATORY MANUAL. 2nd Ed . Cold Sprmg Harbor Laboratory Press. Cold Sprmg Harbor. N Y (1989). such as. calcium phosphate transfection, DEAE-dextran mediated transfection. transvection. microinjection. cationic pid- mediated transfection, electroporation. transduction, scrape loading, ballistic introduction and infection Representative examples of appropπate hosts mclude bactenal cells, such as streptococci. staphvlococci. enterococci E coli. streptomyces and Bacillus subtilis cells, fungal cells, such as yeast cells and Aspergillus cells, insect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS, HeLa, C127, 3T3. BHK. 293 and Bo es melanoma cells, and plant cells A great vanety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude. among others, chromosomal, episomal and vmis-denved vectors. e g . vectors denved from bactenal plasmids. from bactenophage. from transposons. from yeast episomes. from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40. vaccinia viruses, adenoviruses. fowl pox viruses, pseudorabies viruses and retroviruses. and vectors denved from combinations thereof, such as those denved from plasmid and bactenophage genetic elements, such as cosrmds and phagemids The expression system constructs may contain control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and or to express a polypeptide m a host may be used for expression m this regard The appropnate DNA sequence may be inserted mto the expression system by any of a vanety of well-known and routine techniques, such as. for example, those set forth m Sambrook et al . MOLECULAR CLONING. A LABORATORY MANUAL, (supra) For secretion of the translated protem mto the lumen of the endoplasmic reticulum. mto the penplasmic space or mto the extracellular environment, appropπate secretion signals may be incorporated mto the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and punfied from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography. phosphocellulose chromatography. hydrophobic mteraction chromatography. affinity chromatography. hydroxy lapatite chromatography. and lectm chromatography Most preferably, high performance liquid chromatography is emploved for punfication Well known techniques for refolding protem may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or punfication Diagnostic Assays This mvention is also related to the use of the era polvnucleotides of the mv ention for use as diagnostic reagents Detection of era m a eukaryote. particularly a mammal, and especially a human. will provide a diagnostic method for diagnosis of a disease Eukaryotes (herem also "ιndιvιdual(s)"). particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compnsmg the era gene may be detected at the nucleic acid level by a vanety of techniques Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin Genomic DNA may be used directly for detection or may be amplified enzymatically by usmg PCR or other amplification technique pnor to analysis RNA or cDNA may also be used m the same ways Usmg amplification, characterization of the species and stram of prokaryote present m an individual, may be made by an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change m size of the amplified product m companson to the genotype of a reference sequence Pomt mutations can be identified by hybndizmg amplified DNA to labeled era polynucleotide sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in meltmg temperatures DNA sequence differences may also be detected by alterations m the electrophoretic mobility of the DNA fragments m gels, with or without denaturing agents, or by direct DNA sequencmg See, e g , Myers et al . Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method See. e g . Cotton et al . Proc Natl Acad Sci USA, 85 4397-4401 (1985) Cells carry mg mutations or polymorphisms in the gene of the mvention may also be detected at die DNA level by a vanety of techniques, to allow for serotyping, for example For example. RT- PCR can be used to detect mutations It is particularlv prefened to used RT-PCR in conjunction with automated detection systems, such as. for example. GeneScan RNA or cDNA may also be used for the same purpose, PCR or RT-PCR As an example, PCR primers complementary to a nucleic acid encodmg era can be used to identify and analyze mutations Examples of representative primers are shown below m Table 2 Table 2 Primers for amplification of era polynucleotides SEQ ID NO PRIMER SEQUENCE 5 5'-AAGGTTTCCAATATTTCCCGTCTG^-3' 6 5'-ATAGCGCCACCTTTACCGATGAT-3' The mvention further provides these primers with 1. 2. 3 or 4 nucleotides removed from the 5' and/or the 3' end These primers may be used for, among other things, amplifying era DNA isolated from a sample denved from an individual The primers may be used to amplrfv the gene isolated from an infected individual such that the gene may then be subject to vanous techmques for elucidation of the DNA sequence In this way, mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and or classif the infectious agent The mvention further provides a process for diagnosing, disease, preferably bactenal mfections, more preferably infections by Streptococcus pneumomae. and most preferably otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospmal fluid, compnsmg determining from a sample denved from an individual a increased level of expression of polynucleotide havmg the sequence of Table 1 [SEQ ID NO 1] Increased or decreased expression of era polvnucleotide can be measured using anv on of the methods well known m the art for the quantation of polynucleotides. such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybndization methods In addition, a diagnostic assay m accordance w th the mvention for detectmg over- expression of era protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techmques that can be used to determme lev els of a era protem m a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radioimmunoassays. competitive-binding assays. Western Blot analysis and ELISA assays Antibodies The polypeptides of the mvention or vanants thereof, or cells expressmg them can be used as an immunogen to produce antibodies immunospecific for such polypeptides "Antibodies" as used herem includes monoclonal and pol clonal antibodies, chimenc, smgle chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobulin expression library Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-beaπng fragments, analogues or cells to an animal, preferably a nonhuman. usmg routme protocols For preparation of monoclonal antibodies, any technique known m the art that provides antibodies produced by contmuous cell lme cultures can be used Examples mclude vanous techmques. such as those in Kohier. G and Milstem. C . Nature 256 495-497 (1975), Kozbor et al . Immunology Today 4 72 (1983). Cole et al . pg 77-96 m MONOCLONAL ANTIBODIES AND CANCER THERAPY. Alan R Liss. Ine (1985) Techmques for the production of smgle cham antibodies (U S Patent No 4.946.778) can be adapted to produce smgle cham antibodies to polypeptides of this mvention Also, transgemc mice. or other organisms such as other mammals, may be used to express humanized antibodies Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-era or from naive hbranes (McCafferty. J et al . (1990), Nature 348. 552-554, Marks. J et al . (1992) Biotechnology 10. 779-783) The affinity of these antibodies can also be improved by chain shuffling (Clackson. T et al . (1991) Nature 352. 624-628) If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressmg the polypeptides to punfy the polypeptides by affinity chromatography Thus, among others, antibodies against era- polypeptide may be employed to treat infections, particularly bactenal infections and especially otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospmal fluid Polypeptide vanants mclude antigenically, epitopically or immunologically equivalent vanants that form a particular aspect of this invention The term "antigenically equivalent deπvative" as used herein encompasses a polypeptide or its equivalent which will be specificallv recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host The term "immunologically equivalent denvative" as used herein encompasses a peptide or its equivalent which when used m a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere w ith the immediate phy sical interaction between pathogen and mammalian host The polypeptide. such as an antigenically or immunologically equivalent denv ative or a fusion protem thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken The fusion protein may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an lmmunogenic earner protein for example bovme serum albumin (BSA) or keyhole limpet haemocyanin (KLH) Alternatively a multiple antigenic peptide compnsmg multiple copies of the protein or polypeptide, or an antigemcallv or immunologically equivalent polypeptide thereof mav be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier Preferably, the antibody or vanant thereof is modified to make it less lmmunogenic m the individual For example, if the individual is human the antibody may most preferably be "humanized", where the complrmentanty determining regιon(s) of the hybndoma-denved antibody has been transplanted into a human monoclonal antibody . for example as descnbed in Jones. P et al (1986), Nature 321. 522-525 or Tempest et al , (1991) Biotechnology 9, 266-273 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA mto muscles (Wolff et al . Hum Mol Genet 1992, 1 363. Manthorpe et al . Hum Gene Ther 1963 4. 419). delivers of DNA complexed with specific protem earners (Wu et al . J Biol Chem 1989 264.16985). coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef PNAS USA 1986 83.9551). encapsulation of DNA m vanous forms of hposomes (Kaneda et al Science 1989 243,375), particle bombardment (Tang et al Nature 1992. 356 152. Eisenbraun et al DNA Cell Biol 1993, 12 791) and in vivo mfection using cloned retroviral vectors (Seeger et al . PNAS USA 1984 81,5849) Antagonists and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the bmdmg of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical hbranes. and natural product mixtures These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics See. e g . Cohgan et al . Current Protocols in Immunology 1(2) Chapter 5 (1991) The mvention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of era polypeptides or polynucleotides. particularly those compounds that are bactenostatic and or bacteπocidal The method of screening may mvolve high-throughput techmques For example, to screen for agonists or antagoists. a synthetic reaction mix. a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg era polypeptide and a labeled substrate or ligand of such polypeptide is incubated m the absence or the presence of a candidate molecule that may be a era agonist or antagonist The ability of the candidate molecule to agonize or antagonize the era polypeptide is reflected m decreased bmdmg of the labeled ligand or decreased production of product from such substrate Molecules that bmd gratuitously, i e . without inducing the effects of era polypeptide are most likely to be good antagonists Molecules that bmd well and mcrease the rate of product production from substrate are agonists Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful in this regard mclude but are not limited to colonmetnc labeled substrate converted mto product, a reporter gene that is responsive to changes m era polynucleotide or polypeptide activity, and bmdmg assays known in the art Another example of an assay for era antagomsts is a competitive assay that combmes era and a potential antagonist with era-binding molecules, recombinant era bmdmg molecules, natural substrates or ligands, or substrate or ligand mimetics. under appropnate conditions for a competitive inhibition assay The era molecule can be labeled, such as by radioactivity or a colonmetnc compound, such that the number of era molecules bound to a bmdmg molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist Potential antagonists mclude small organic molecules, peptides. polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagomsts also may be small orgamc molecules, a peptide, a polypeptide such as a closely related protem or antibody that bmds the same sites on a bmdmg molecule, such as a bmdmg molecule, without inducing era-induced activities, thereby preventmg the action of era by excluding era from bmdmg Potential antagomsts mclude a small molecule that bmds to and occupies the bmdmg site of the polypeptide thereby preventing bmdmg to cellular bmdmg molecules, such that normal biological activ ltv is prevented Examples of small molecules mclude but are not limited to small orgamc molecules, peptides or peptide-like molecules Other potential antagomsts mclude antisense molecules (see Okano. ./ Neurochem 56 560 (1991). OUGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION. CRC Press. Boca Raton. FL (1988). for a descnption of these molecules) Prefened potential antagomsts mclude compounds related to and vanants of era Each of the DNA sequences provided herein may be used in the discovery and development of antibacteπal compounds The encoded protein, upon expression, can be used as a target for the screening of antibactenal drugs Additionally, the DNA sequences encoding the ammo terminal regions of the encoded protem or Shine-Delgamo or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the codmg sequence of mterest The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection In particular the molecules of the invention may be used in the prevention of adhesion of bacteria, m particular gram positive bactena. to mammalian extracellular matnx protems on in-dwelling devices or to extracellular matnx protems in wounds, to block era protein-mediated mammalian cell invasion by, for example, mitiatmg phosphorylation of mammalian tv rosine kmases (Rosenshine et al . Infect Immun 60 221 1 (1992), to block bactenal adhesion between mammalian extracellular matnx protems and bactenal era protems that mediate tissue damage and. to block the normal progression of pathogenesis m infections initiated other than by the implantation of in-dwelling devices or by other surgical techmques The antagomsts and agonists of the mvention may be employed, for instance, to inhibit and treat otitis media, conjunctivitis, pneumonia, bacteremia. meningitis, sinusitis, pleural empy ema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid Helicobacter pylori (herein// pylori) bactena infect the stomachs of over one-third of the world's population causmg stomach cancer, ulcers, and gastntis (International Agency for Research on Cancer (1994) Schistosomes. Liver Flukes and Helicobacter Pylon (International Agency for Research on Cancer, Lyon. France, http //www uicc ch/ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H pylori and gastnc adenocarcinoma, classifying the bactenum as a Group I (definite) carcinogen Preferred antimicrobial compounds of the invention (agonists and antagonists of era) found usmg screens provided by the invention, particularly broad- spectrum antibiotics, should be useful in the treatment of// pylori infection Such treatment should decrease the advent of H /ry/oπ-induced cancers, such as gastrointestinal carcinoma Such treatment should also cure gastnc ulcers and gastntis Vaccines Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which compnses inoculating the individual with era. or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from mfection. particularly bactenal infection and most particularly Streptococcus pneumomae infection Also provided are methods whereby such immunological response slows bactenal replication Yet another aspect of the invention relates to a method of inducing immunological response in an individual which compnses delivering to such individual a nucleic acid vector to direct expression of era. or a fragment or a vanant thereof, for expressing era. or a fragment or a variant thereof in vivo in order to induce an immunological response, such as to produce antibody and/ or T cell immune response, including, for example, cytokme-producmg T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not One way of administenng the gene is by accelerating it mto the desired cells as a coating on particles or otherwise Such nucleic acid vector may compnse DNA. RNA. a modified nucleic acid, or a DNA/RNA hybnd A further aspect of the mvention relates to an immunological composition which, when mtroduced mto an individual capable or havmg induced within it an immunological response, mduces an immunological response m such individual to a era or protein coded therefrom. wherem the composition compnses a recombinant era or protem coded therefrom compnsmg DNA which codes for and expresses an antigen of said era or protein coded therefrom The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that ansmg from CTL or CD4+ T cells A era polypeptide or a fragment thereof may be fused with co-protem which may not by itself produce antibodies, but is capable of stabilizing the first protem and producmg a fused protem which will have lmmunogenic and protective properties Thus fused recombinant protein, preferably further compnses an antigenic co-protem. such as hpoprotein D from Hemophilus infiuenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubihze the protem and facilitate production and punfication thereof Moreover, the co-protem may act as an adjuvant in the sense of providing a generalized stimulation of the immune system The co-protein may be attached to either the amino or carboxy terminus of the first protem Provided by this invention are compositions, particularly vaccine compositions, and methods compnsmg the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato Y et al Science 273 352 (1996) Also, provided by this invention are methods using the descnbed polynucleotide or particular fragments thereof which ha e been shown to encode non-vanable regions of bactenal cell surface proteins m DNA constructs used m such genetic immunization expenments in animal models of mfection with Streptococcus pneumomae will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing mfection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Streptococcus pneumomae infection, in mammals, particularly humans The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bactena, for example by blocking adherence of bactena to damaged tissue Examples of tissue damage mclude wounds m skin or connective tissue caused, e g , by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds m the mucous membranes, such as the mouth, mammary glands, urethra or vagma The invention also includes a vaccine formulation which compnses an lmmunogenic recombinant protem of the invention together with a suitable earner Since the protem may be broken down in the stomach, it is preferably administered parenterally , including, for example administration that is subcutaneous, intramuscular, intravenous, or intradermal Formulations suitable for parenteral administration mclude aqueous and non-aqueous stenle injection solutions which may contain anti-oxidants. buffers, bactenostats and solutes which render the formulation msotomc with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous stenle suspensions which may include suspendmg agents or thickening agents The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dned condition requinng only the addition of the stenle liquid earner immediately pnor to use The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art The dosage will depend on the specific activity of the vaccine and can be readily determined by routine expenmentation While the invention has been descnbed with reference to certain era protem. it is to be understood that this covers fragments of the naturally occurnng protein and similar proteins with additions, deletions or substitutions which do not substantially affect the lmmunogenic properties of the recombinant protein Compositions, kits and administration The mvention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agomsts or antagomsts The polypeptides of the mvention may be employed m combmation with a non-stenle or stenle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for administration to a subject Such compositions compnse. for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude. but are not limited to. salme, buffered salme. dextrose, water, glvcerol. ethanol and combmations thereof The formulation should suit the mode of administration The mvention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention may be employed alone or m conjunction with other compounds, such as therapeutic compounds The pharmaceutical compositions may be administered m any effective, convement manner including, for instance, administration by topical, oral. anal, vaginal, intravenous, mtrapentoneal. intramuscular, subcutaneous, mtranasal or intradermal routes among others In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a stenle aqueous dispersion, preferably isotonic Alternatively the composition may be formulated for topical application for example in the form of omtments, creams, lotions, eye omtments. eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropnate conventional additives, mcludmg, for example, preservatives, solvents to assist drug penetration, and emollients m omtments and creams Such topical formulations may also contain compatible conventional earners, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions Such earners may constitute from about 1% to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg/kg to 10 mg/kg. typically around 1 mg/kg The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age. weight and response of the particular individual The above dosages are exemplary of the average case There can, of course, be individual instances where higher or lower dosage ranges are mented. and such are within the scope of this mvention In-dwelling devices mclude surgical implants, prosthetic devices and catheters, i e . dev ices that are introduced to the body of an individual and remain in position for an extended time Such devices mclude, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, unnary catheters, contmuous ambulatory pentoneal dialysis (CAPD) catheters The composition of the invention may be administered by injection to achieve a systemic effect against relevant bactena shortly before insertion of an in-dwelling device Treatment may be continued after surgery dunng the m-body time of the device In addition, the composition could also be used to broaden penoperati e cover for any surgical technique to prevent bactenal wound infections, especially Streptococcus pneumomae wound infections Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep infection is a senous complication sometimes leadmg to loss of the prosthetic joint and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics m this situation In addition to the therapy descnbed above, the compositions of this mvention may be used generally as a wound treatment agent to prevent adhesion of bactena to matnx protems exposed in wound tissue and for prophylactic use m dental treatment as an altemativ e to. or m conjunction with, antibiotic prophylaxis Alternatively, the composition of the mvention may be used to bathe an indwelling device immediately before insertion The active agent will preferably be present at a concentration of 1 μg/ml to lOmg ml for bathing of wounds or indwelling devices A vaccme composition is conveniently m mjectable form Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccination is 0 5-5 microgra /kg of antigen, and such dose is preferably administered 1-3 tunes and with an interval of 1-3 weeks With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals Each reference disclosed herein is incorporated by reference herem in its entirety Any patent application to which this application claims pnonty is also incorporated by reference herein m its entiretv EXAMPLES The examples below are earned out usmg standard techmques. which are well known and routme to those of skill m the art. except where otherwise descnbed in detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The polynucleotide having the DNA sequence given in SEQ ID NO 1 was obtained from a library of clones of chromosomal DNA of Streptococcus pneumomae in E cob The sequencing data from two or more clones containing overlapping Streptococcus pneumomae DNAs was used to construct the contiguous DNA sequence in SEQ ID NO 1 Libranes may be prepared by routine methods, for example Methods 1 and 2 below Total cellular DNA is isolated from Streptococcus pneumomae 0100993 according to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size-fractionate according to standard procedures DNA fragments of up to l lkbp m size are rendered blunt by treatment with exonuclease and DNA polymerase. and EcoRI linkers added Fragments are ligated mto the vector Lambda ZapII that has been cut with EcoRI. the library packaged by standard procedures and E cob infected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combmation of restnction enzymes appropπate to generate a senes of fragments for clonmg mto library vectors (e g Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated accordmg to standard procedures EcoRI linkers are ligated to the DNA and the fragments then ligated mto the vector Lambda ZapII that have been cut with EcoRI. the library packaged by standard procedures, and E cob infected with the packaged library The library is amplified by standard procedures Example 2 era Characterization Charactenzation of Era Gene Expression Gene expression in vivo Recently several novel approaches have been descnbed which purport to follow global gene expression dunng infection (Chuang, S et al , (1993). Mahan. M J et al . Science 259 686-688 (1993). Hensel. M et al , Science 269 400-403 (1995) These new techniques have so far been demonstrated with gram negative pathogen infections but not with infections with gram positives presumably because the much slower development of global transposon mutagenesis and suitable vectors needed for these strategies in these organisms, and in the case of that process descnbed by Chuang. S et al , J Bactenol 175 2026-2036 (1993) the difficulty of isolating suitable quantities of bactenal RNA free of mammalian RNA denved from the infected tissue to furnish bactenal RNA labelled to sufficiently high specific activity The present invention employ s a novel technology to determine gene expression in the pathogen at different stages of infection of the mammalian host Use of the technology of the present invention enables identification of bactenal genes transcnbed dunng infection inhibitors of which would have utility m anti-bactenal therapv Specific inhibitors of such gene transcnption or of the subsequent translation of the resultant mRNA or of the function of the corresponding expressed proteins would have utility m anti- bactenal therapy The determination of expression dunng mfection of a gene from Streptococcus pneumomae Lung tissue from a 48 hr pneumonia infection of Streptococcus pneumomae 100993 in the mouse is efficiently disrupted and processed in the presence of acid phenol and detergent to provide a mixture of animal and bactenal RNA By freezing the tissue immediately m liquid nitrogen, and processing the tissue samples while still frozen, changes m the population of bactenal mRNA is minimized The resultant total RNA is free of DNA and protein (mcludmg RNAases and DNAases) The optimal conditions for disruption and processing to give high yields of bactenal mRNA with transcnpts of long length are followed by reverse transcnbing the resulting mRNA to cDNA and amplified with ORF-specific pnmers for a bactenal gene known to be expressed constitutively and at low copy number Aspects of this example II. part b. are modifications of a published protocol (Cheung, et al , Anal Biochem (1994) 222 51 1- 514) a) Isolation of lung tissue infected with Streptococcus pneumomae 0100993 from a mouse respiratory tract infection model Streptococcus pneumomae 100993 was seeded onto TSA (Tryptic Soy Agar. BBL) plates contammg 5% horse blood and allowed to grow overnight at 37°C m a C02 mcubator Bactenal growth was scraped into 5 ml of phosphate-buffered salme (PBS) and adjusted to an A600 ~ 0 6 (4 x 106/ml) Mice (male CBA/J-1 mice, approximately 20g) were anaesthetized with isoflurane and 50 microhters of the prepared bactenal inoculum was delivered by mtranasal instillation Animals were allowed to recover and observed twice daily for signs of monbundancy Forty-eight hours after infection the animals were euthanized by carbon dioxide overdose and their torsos swabbed with ethanol and then RNAZap The torso was then opened, and the lungs were aseptically removed Half of each pair of lungs was placed m a cryovial and immediately frozen in liquid nitrogen, the other half was used for bactenal enumeration after homogenization of the tissue m 1 ml of PBS b) Isolation of Streptococcus pneumomae 0100993 RNA from infected tissue samples Infected tissue samples, m 2-ml cryo-strorage tubes, are removed from liquid nitrogen storage for immediate processing of the frozen tissue In a microbiological safety cabinet the samples are disrupted up to eight at a time To disrupt the bactena withm the tissue sample. 50-100 mg of the tissue is transfered to a FastRNA tube containing a silica/ceramic matnx (BIO 101) Immediately. 1 ml of extraction reagents (FastRNA reagents. BIOlOl) are added to give a sample to reagent volume ratio of approximately 1 to 20 The tubes are shaken m a reciprocating shaker (FastPrep FP120. BIOlOl) ata setting of 5 5 to 6 for 20-120 sec The crude RNA preparation is extracted with chloroform/isoamyl alcohol, and precipitated with DEPC-treated/Isopropanol Precipitation Solution (BIOlOl) RNA preparations are stored in this isopropanol solution at -80°C if necessary The RNA is pelleted (12.000g for 10 min ). washed with 75% ethanol (v/v m DEPC-treated water), air-dned for 5-10 mm. and resuspended in 0 1 ml of DEPC-treated water Quality of the RNA isolated is assessed by the ability to detect bactenal transcnpts up to 2 kb in length by RT-PCR (as descnbed below m section) To demonstrate the isolation of bactenal RNA from the infected tissue, samples of RNA are reverse transcnbed. and the presence of a constitutively expressed gene is detected through the use of quantitative PCR m the presence of a TaqMan probe (as descnbed below) c) The removal of DNA from Streptococcus pneumomae (0100993 )-denved RNA DNA was removed from 50 microgram samples of RNA by a 30 mmute treatment at 37°C with 10 units of RNAase-free DNAasel (GeneHunter) in the buffer supplied m a final volume of 57 microhters The DNAase was inactivated and removed by phenol chloroform extraction RNA was precipitated with 5 microhters of 3 M NaOAc and 200 microhters 100% EtOH, and pelleted by centnfugation at 12.000g for 10 minutes The RNA is pelleted (12.000g for 10 mm ), washed with 75% ethanol (v/v m DEPC-treated water), air-dned for 5-10 mm. and resuspended m 10-20 microhters of DEPC-treated water RNA yield is quantitated by OD260 after 1 1000 dilution of the cleaned RNA sample RNA is stored at -80°C if necessary and reverse-transcnbed within one week d) The preparation of cDNA from RNA samples denved from mfected tissue 10 microhter samples of DNAase treated RNA are reverse transcnbed usmg a SuperScnpt Preamphfication System for First Strand cDNA Synthesis kit (Gibco BRL, Life Technologies) according to the manufacturers instructions 1 nanogram of random hexamers is used to prime each reaction Controls without the addition of SuperScnptll reverse transcnptase are also run Both +/-RT samples are treated with RNaseH before proceeding to the PCR reaction e) The use of PCR to determme the quality of bactenal RNA denved from mfected tissue Long transcnpts, which are expected to be of low copy number within the bactenal cell, such as penicillin-binding protein 2 (PBP2), are reverse transcnbed with random primers as descnbed above and amplified by the following PCR method using ORF -specific primers, m order to ascertain the quality, represented by length amplified, of the mRNA obtained dunng extraction and punfication PCR reactions are set up on ice m 0 2 ml tubes m a total volume of 50 ul by adding the following components [final concentration] AmpliTaq PCR Buffer II (IX), 1 5mM MgCL2. 1 mM dNTPs, 0 5uM forward pnmer, 0 5uM reverse pnmer. and 2 ul reverse-transcnbed RNA PCR reactions are run on a PE GeneAmp PCR System 9600 with an initial step of 94oC for 2mm, followed by 35 cycles of 94 oC for 30sec. 42 oC for 30sec and 72 oC for 30sec. followed by a final extensison at 72 oC for 7mm f) The use of PCR to determme the presence of a bactenal cDNA species PCR reactions are set up as descnbed above usmg 0 5 microM each of the ORF specific forward and reverse primers PCR product in 20 microhter ahquots are separated by electrophoresis through 1 to 1 5% 1 x TBE agarose gels or 10% lx TBE acrylamide gels PCR product is visualized by staining the gel with ethidium bromide Size estimates are made by companson to a 100 bp DNA Ladder (Gibco BRL, Life Technologies) Alternatively, if the PCR products are conveniently labelled by the use of a labelled PCR pnmer (e g labelled at the 5'end with a dye) a suitable aliquot of the PCR product is run out on a polyacrylamide sequencmg gel and its presence and quantity detected using a suitable gel scanning system (e g ABI PπsmTM 377 Sequencer using GeneScanTM software as supplied bv Perkin Elmer) RT/PCR controls may include +/- reverse transcnptase reactions, 16s rRNA pnmers or DNA specific pnmer pairs designed to produce PCR products from non-transcnbed Staphylococcus aureus WCUH29 genomic sequences To test the efficiency of the pnmer pairs they are used in DNA PCR with Staphylococcus aureus WCUH29 total DNA PCR reactions are set up and run as descnbed above using approx 1 microgram of DNA in place of the cDNA and 35 cycles of PCR Pnmer pairs which fail to give the predicted sized product in either DNA PCR or RT/PCR are PCR failures and as such are uninformative Of those which give the conect size product with DNA PCR two classes are distinguished in RT/PCR 1 Genes which are not transcnbed in vivo reproducibly fail to give a product in RT/PCR, and 2 Genes which are transcnbed m vivo reproducibly give the correct size product m RT PCR and show a stronger signal m the +RT samples than the signal (if at all present) m -RT controls g) The use of PCR and fluorogenic probes to determme the presence of a bactenal cDNA species Specific sequence detection occurs by amplification of target sequences m the PE Applied Biosystems 7700 Sequence Detection System m the presence of an ohgonucleotide probe labeled at the 5' and 3' ends with a reporter and quencher fluorescent dye, respectively (FQ probe), which anneals between the two PCR pnmers Only specific product will be detected when the probe is bound between the pnmers As PCR amplification proceeds, the 5'- nuclease activity of Taq polymerase initially cleaves the reporter dye from the probe The signal generated when the reporter dye is physically separated from the quencher dye is detected by measurmg the signal with an attached CCD camera Each signal generated equals one probe cleaved which coπesponds to amplification of one target strand PCR reactions are set up usmg the PE Applied Biosystem TaqMan PCR Core Reagent Kit according to the instructions supplied such that each reaction contains 5 microhters 1 OX PCR Buffer II, 7 microhters 25 mM MgC12, 5 microhters 300 nM forward pnmer, 5 microhters reverse pnmer, 5 microhters specific FQ probe. 1 microhter each 10 mM dATP. 10 mM dCTP, 10 mM dGTP and 20 mM dUTP, 13 25 microhters distilled water, 0 5 microhters AmpErase UNG, and 0 25 microhters AmpliTaq DNA polymerase to give a total volume of 45 microhters Amplification proceeds under the following thermal cycling conditions 50°C hold for 2 minutes. 95°C hold for 10 minutes. 40 cycles of 95°C for 15 seconds and 60°C for 1 minute, followed by a 25°C hold until sample is retneved Detection occurs real-time Data is collected at the end of the reaction Based on these analyses it was discovered that the Streptococcus pneumomae era gene was transcnbed in vivo

Claims: What is claimed is: 1 An isolated polynucleotide compnsmg a polynucleotide sequence selected from the group consisting of (a) a polynucleotide havmg at least a 92% identity to a polynucleotide encodmg a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2, (b) a polynucleotide havmg at least a 92% identity to a polynucleotide encodmg the same mature polypeptide expressed by the era gene contamed m the Streptococcus pneumomae of the deposited stram. (c) a polynucleotide encodmg a polypeptide compnsmg an ammo acid sequence which is at least 92% identical to the ammo acid sequence of SEQ ID NO 2 (d) a polynucleotide which is complementary to the polynucleotide of (a), (b) or (c). and (e) a polynucleotide compnsmg at least 15 sequential bases of the polynucleotide of (a), (b), (c) or (d) 2 The polynucleotide of Claim 1 wherem the polynucleotide is DNA 3 The polynucleotide of Claim 1 wherem the polynucleotide is RNA 4 The polynucleotide of Claim 2 compnsmg the nucleic acid sequence set forth in SEQ ID NO 1 5 The polynucleotide of Claim 2 compnsmg nucleotide 1 to 898 set forth m SEQ ID NO l 6 The polynucleotide of Claim 2 which encodes a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 7 A vector compnsmg the polynucleotide of Claim 1 8 A host cell compnsmg the vector of Claim 7 9 A process for producmg a polypeptide compnsmg expressmg from the host cell of Claim 8 a polypeptide encoded by said DNA 10 A process for producmg a era polypeptide or fragment compnsmg cultunng a host of claim 8 under conditions sufficient for the production of said polypeptide or fragment 1 1 A polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 12 A polypeptide compnsmg an ammo acid sequence as set forth m SEQ ID NO 2 13 An antibody against the polypeptide of claim 11 14 An antagonist which inhibits the activity or expression of the polypeptide of claim 11 15 A method for the treatment of an mdividual m need of era polypeptide compnsmg administering to the mdividual a therapeutically effective amount of the polypeptide of claim 11 16 A method for the treatment of an mdividual havmg need to inhibit era polvpeptide compnsmg admmistermg to the mdividual a therapeutically effective amount of the antagomst of Claim 14 17 A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an mdividual compnsmg (a) determining a nucleic acid sequence encodmg said polypeptide, and/or (b) analyzing for the presence or amount of said polypeptide m a sample denved from the mdividual 18 A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 compnsmg contacting a composition compnsmg the polypeptide with the compound to be screened under conditions to permit mteraction between the compound and the polypeptide to assess the mteraction of a compound, such mteraction bemg associated with a second component capable of providing a detectable signal in response to the mteraction of the polypeptide with the compound. and determining whether the compound interacts with and activates or inhibits an activity of the polypeptide by detectmg the presence or absence of a signal generated from the mteraction of the compound with the polypeptide 19 A method for inducing an immunological response m a mammal which compnses inoculating the mammal with era polypeptide of claim 11, or a fragment or vanant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease 20 A method of inducing immunological response m a mammal which compnses delivering a nucleic acid vector to direct expression of era polypeptide of claim 11. or fragment or a vanant thereof, for expressmg said era polypeptide, or a fragment or a vanant thereof in vivo m order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease

Inventors: BLACK MICHAEL T, HODGSON JOHN E, KNOWLES DAVID J C, LONETTO MICHAEL A, NICHOLAS RICHARD O, PALMER LESLIE MARIE, REID ROBERT, ROSENBERG MARTIN, ZARFOS PHILLIP, BLACK, MICHAEL, T., HODGSON, JOHN, E., KNOWLES, DAVID, J., C., LONETTO, MICHAEL, A., NICHOLAS, RICHARD, O., PALMER, LESLIE, MARIE, REID, ROBERT, ROSENBERG, MARTIN, ZARFOS, PHILLIP
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K45, A61P31, A61P37, C07K14, C07K16, C12N1, C12N15, C12P21, C12Q1, G01N33